Pune, October 3 (Udaipur Kiran) : The Maharashtra Food and Drug Administration (FDA) has revoked the license of Cipla Pharma and Life Sciences Limited’s carrying and forwarding (C&F) warehouse located in Wadki, Pune. This action, taken on October 1, follows a review prompted by directives from the Bombay High Court, which highlighted several alleged deficiencies related to drug packaging, storage, stock management, and documentation.
The FDA had initiated action against the warehouse on August 27 but later reconsidered the case under a revised procedure. Concerns were raised regarding the packaging and promotion of the prescription drug ‘Reactin Plus Tablets,’ which was reportedly marketed with unauthorized claims. Additionally, the FDA found several shortcomings in the storage practices and handling of expired medications at the warehouse.
Following the High Court’s instructions, the FDA issued a revised show-cause notice to Cipla on September 4. The company responded in writing on September 11 and presented its case during a personal hearing on September 21. After reviewing the company’s response, records, and relevant legal provisions, the licensing authority decided to revoke the warehouse’s license based on the findings from the renewed investigation.
The FDA emphasized that this decision was based on facts uncovered during the comprehensive review process and was not merely a repetition of previous actions. Key issues identified included misleading claims on the packaging of ‘Reactin Plus,’ which suggested its use for pain relief in various conditions, accompanied by images depicting human figures and indications of muscle pain relief.
This development underscores the FDA’s commitment to ensuring compliance with regulations governing drug safety and marketing practices.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.